INDEXES Author Index to Volume 35* A cholangiocyte growth and secretion of Araco A (see Angelico M et al). 2002;35: BDL rats through activation of PKC 176-181 Abeygunasekera S (see Chitturi S et al). alpha. 2002;35:1041-1052 Arias IM (see Ortiz D et al). 2002;35:1548 2002;35:373-379 —, McGill JM, LaRusso NF. The (Correspondence) Abid K (see Latorre P et al). 2002;35:239- pathobiology of biliary epithelia. — (see Ujhazy P et al). 2002;35:246 240 (Correspondence) 2002;35:1256-1268 (Special Article) (Correction) Abiru S, Nakao K, Ichikawa T, Migita K, Alter HJ (see Umemura T et al). 2002;35: Arii S (see Yasui K et al). 2002;35:1476- Shigeno M, Sakamoto M, Ishikawa 953-959 1484 H, Hamasaki K, Nakata K, Eguchi K. —. Hepatology Highlights. 2002;35:1-2, Aronow BJ (see Kelley-Loughnane N et al). Aspirin and NS-398 inhibit 741-742 2002;35:525-534 hepatocyte growth factor-induced Alvarez E (see Salcedo M et al). 2002;35: Arroyo V (see FernandezJ et al). 2002;35: invasiveness of human hepatoma cells. 349-356 140-148 2002;35:1117-1124 Amaki S (see Shibuya A et al). 2002;35: Arvelo MB, Cooper JT, Longo C, Daniel Abraldes JG, Bosch J. Somatostatin and 1172-1178 S, Grey ST, Mahiou J, Czismadia E, analogues in portal hypertension. Amersi F, Shen X-D, Anselmo D, Melinek Abu-Jawdeh G, Ferran C. A20 2002;35:1305-1312 (Perspectives in J, lyer S, Southard DJ, Katori M, protects mice from D-galactosamine/ Clinical Hepatology) Volk H-D, Busuttil RW, Buelow R, lipopolysaccharide acute toxic lethal Abu-Elmagd KM (see Dvorchik I et al). Kupiec-Weglinski JW. Ex vivo hepatitis. 2002;35:535-543 2002;35:380-384 exposure to carbon monoxide Asara G (see Pascale RM et al). 2002;35: Abu-Jawdeh G (see Arvelo MB et al). 2002; prevents hepatic ischemia/reperfusion 1341-1350 35:535-543 injury through p38 MAP kinase Ashour Y (see Galun E et al). 2002;35:673- Adachi $, Okuno M, Matsushima- pathway. 2002;35:815-823 679 Nishiwaki R, Takano Y, Kojima S, Amouzadeh HR (see Bourdi M et al). 2002; — (see Galun E et al). 2002;35:986 Friedman SL, Moriwaki H, Okano Y. Phosphorylation of retinoid X 35:289-298 (Correction) Anania FA (see Rai R et al). 2002;35:1247- Astemborski J (see Rai R et al). 2002;35: receptor suppresses its ubiquitination 1247-1455 in human hepatocellular carcinoma. — (see1 4S5a5x ena NK et al). 2002;35:762-771 Aubert D (see Auvigne | et al). 2002;35: 2002;35:332-340 Angeli P (see Bolognesi M et al). 2002;35: 281-288 Adami G (see Tan Y et al). 2002;35:790- Audet P (see Fabre A et al). 2002;35:414- 601-608 798 420 Angelico M (see Alpini G et al). 2002;35: Agell N (see Jaime M et al). 2002;35:1063- Auvigne I, Pichard V, Aubert D, Robillard 1071 1041-1052 N, Ferry N. Jn vivo cell lineage Agteresch HJ (see Leij-Halfwerk S et al). —, Di Paolo D, Trinito MO, Petrolati A, analysis in cyproterone acetate—treated Araco A, Zazza S, Lionetti R, 2002;35:421-424 rat liver using genetic labeling of Casciani CU, Tisone G. Failure of a Albillos A (see Banares R et al). 2002;35: hepatocytes. 2002;35:281-288 reinforced triple course of hepatitis 609-615 Avila MA (see Ansorena E et al). 2002;35: Albrecht JK (see McHutchison JG et al). B vaccination in patients 274-280 transplanted for HBV-related 2002;35:688-693 Azzaroli F (see Mazzella G et al). 2002;35: Aldeguer X, Debonera F, Shaked A, cirrhosis. 2002;35:176-181 1291 (Correction) Krasinkas AM, Gelman AE, Que X, Angeloni S (see Riggio O et al). 2002;35: Zamir GA, Hiroyasu S, Kovalovich 501-502 (Correspondence) KK, Taub R, Olthoff KM. Angulo P, Maor-Kendler Y, Lindor KD. Interleukin-6 from intrahepatic cells Small-duct primary sclerosing of bone marrow origin is required for cholangitis: a long-term follow-up Baatar D (see Kawanaka H et al). 2002;35: normal murine liver regeneration. study. 2002;35:1494-1500 393-402 2002;35:40-48 Ansari AA (see Matsumura S et al). 2002; Bachs O (see Jaime M et al). 2002;35: Allada R (see Turek FW et al). 2002;35: 35:14-22 1063-1071 743-745 (Science Frontier) — (see Sasaki M et al). 2002;35:1284-1286 Bacon BR (see Di Bisceglie AM et al). Allsop JM (see Forton DM et al). 2002;35: (Correspondence) 2002;35:500 (Correspondence) 433-439 Anselmo D (see Amersi F et al). 2002;35: Baer HU (see Redaelli CA et al). 2002;35: Alonso S (see Bafiares R et al). 2002;35: 815-823 1082-1092 Bafty G, Zhang C-Y, Glickman JN, Lowell 609-615 Ansorena E, Garcia-Trevijano ER, BB. Obesity-related fatty liver is — (see Salcedo M et al). 2002;35:349-356 Martinez-Chantar ML, Huang Z-Z, unchanged in mice deficient for Alpini G (see Kanno N et al). 2002;35: Chen L, Mato JM, Iraburu M, Lu 1329-1340 SC, Avila MA. S-adenosylmethionine mitochondrial uncoupling protein 2. —., Baiocchi L, Glaser §, Ueno Y, Marzioni and methylthioadenosine are 2002;35:753-761 M, Francis H, Phinizy JL, Angelico antiapoptotic in cultured rat hepatocytes Baiocchi L (see Alpini G et al). 2002;35: M, LeSage G. Ursodeoxycholate and but proapoptotic in human hepatoma 1041-1052 Bakke A (see Rosen HR et al). 2002;35: tauroursodeoxycholate inhibit cells. 2002;35:274-280 190-198 Balasubramanian KA (see Ramachandran A et al). 2002;35:622-629 "January, 1-248; February, 249-506; March, 507-740; April, 741-990; May, 991-1294; June, 1295- Balian A (see Raynard B et al). 2002;35: 1602. 635-638 1561 1562. AUTHOR INDEX HEPATOLOGY, June 2002 Baller JFW (see Plésch T et al). 2002;35: Berg T (see Steinmiiller T et al). 2002;35: Nava V, Angeli P, Feltracco P, Gatta 299-306 1528-1535 A. Change in portal flow after liver Bafiares R (see Escorsell A et al). 2002;35: Bergquist A (see Boberg KM et al). 2002; transplantation: effect on hepatic 385-392 35:652-657 arterial resistance indices and role of — (see Salcedo M et al). 2002;35:349-356 Bernardi M. Renal sodium retention in spleen size. 2002;35:601-608 —., Albillos A, Rincén D, Alonso S, preascitic cirrhosis: expanding Bombonato G (see Bolognesi M et al). Gonzalez M, Ruiz-del-Arbol L, knowledge, enduring uncertainties. 2002;35:601-608 Salcedo M, Molinero L-M. 2002;35:1544-1547 (Editorial) Bonyhay L (see Ratziu V et al). 2002;35: Endoscopic treatment versus Bernstein D, Kleinman L, Barker CM, 1485-1493 endoscopic plus pharmacologic Revicki DA, Green J. Relationship of BorovickaJ (see Helbling B et al). 2002;35: treatment for acute variceal bleeding: health-related quality of life to 447-454 a meta-analysis. 2002;35:609-615 treatment adherence and sustained Bosca L (see Callejas NA et al). 2002;35: Bani D (see Fantappié O et al). 2002;35: response in chronic hepatitis C 341-348 843-852 patients. 2002;35:704-708 Bosch J (see Abraldes JG et al). 2002;35: Baqué P, Pierrefite-Carle V, Gavelli A, Bezerra JA (see Kelley-Loughnane N et al). 1305-1312 (Perspectives in Clinical Brosette N, Benchimol D, Bourgeon 2002;35:525-534 Hepatology) A, Staccini P, Saint-Paul M-C, Rossi Bhargava KK (see Slehria S et al). 2002;35: — (see Escorsell A et al). 2002;35:385-392 B. Naked DNA injection for liver 1320-1328 — (see Perellé A et al). 2002;35:132-139 metastases treatment in rats. 2002;35: Bica I (see McGovern B et al). 2002:35:730 Bourdi M, Masubuchi Y, Reilly TP, 1144-1152 (€ ‘orrespondence) Amouzadeh HR, Martin JL, George Barbu V (see Corpechot C et al). 2002;35: Bilzer M (see Kiemer AK et al). 2002;35: JW, Shah AG, Pohl LR. Protection 88-94 against acetaminophen-induced liver 1010-1021 Barker CM (see Bernstein D et al). 2002; Bini E] (see Chalasani N et al). 2002;35: injury and lethality by interleukin 10: 1282-1284 role of inducible nitric oxide synthase. 35:704-708 Barletta G (see La Villa G et al). 2002;35: Bismuth H (see Sebagh M et al). 2002;35: 2002;35:289-298 117-125 Bourgeon A (see Baqué P et al). 2002;35: 1441-1448 Barrier L (see Dubuisson L et al). 2002;35: Blakolmer K (see Sebagh M et al). 2002;35: 1144-1152 117-125 Boussarie L (see Dubuisson L et al). 2002; 325-331 Bartenschlager R (see Dries V et al). 2002; Blei AT. A new team at a new time. 2002; 35:325-331 35:i(Jan.) (Editorial) Bouwer HGA (see Rosen HR et al). 2002; 35:1552-1553 (Correspondence) — (see Frese M et al). 2002;35:694-703 — (see Ferenci P et al). 2002;35:716-721 35:190-198 Barth K (see Frese M et al). 2002;35:694-703 (Special Article) Bovicelli L (see Mazzella G et al). 2002;35: Barton MC, Stivers DN. Microarray Blendis L (see Wong F et al). 2002;35: 1291 (Correction) 1449-1458 Brass V, Blum HE, Moradpour D. Of mice analysis of hepatic-regulated gene Bloks VW (see Plésch T et al). 2002;35: and men: a small animal model of expression: specific applications and 299-306 hepatitis C virus replication. 2002;35: nonspecific problems. 2002;35:727- Blokzijl H, de Knegt RJ. Long-term effect 722-723 (Hepatology Elsewhere) 729 (Editorial) of treatment of acute Budd-Chiari Brites D (see Rodrigues CMP et al). 2002; Bartsch P (see Fuchs M et al). 2002;35: syndrome with a transjugular 35:1186-1195 241-242 (Correspondence) intrahepatic portosystemic shunt. Bronk SF (see Nzeako UC et al). 2002;35: Bastie A (see Castéra L et al). 2002;35:978- 2002;35:1551-1552 552-559 979 (Correspondence) (Correspondence) Bronner MP (see Raaka S et al). 2002;35: Batts K (see Joshi S et al). 2002;35:409-413 Blum HE (see Brass V et al). 2002;35:722- 977-978 (Correspondence) Bauer T, Weinberger K, Jilg W. Variants of 723 (Hepatology Elsewhere) Broomé U (see Boberg KM et al). 2002;35: two major T cell epitopes within the — (see von Weizsiacker F et al). 2002;35: 652-657 hepatitis B surface antigen are not 209-216 Brosette N (see Baqué P et al). 2002;35: recognized by specific T helper cells of Boberg KM, Rocca G, Egeland T, 1144-1152 vaccinated individuals. 2002;35:455- Bergquist A, Broomé U, Caballeria L, Bru C (see Escorsell A et al). 2002;35:385- 465 Chapman R, Hultcrantz R, Mitchell 392 Beard MR (see Li K et al). 2002;35:1237- S, Pares A, Rosina F, SchrumpfE . Bruix J, Llovet JM. Prognostic prediction 1246 Time-dependent Cox regression and treatment strategy in Beck | (see von Weizsicker F et al). 2002; model is superior in prediction of hepatocellular carcinoma. 2002;35: 35:209-216 prognosis in primary sclerosing 519-524 (Perspectives in Clinical Becker U, Gronbek M, Johansen D, cholangitis. 2002;35:652-657 Hepatology) Sorenson TIA. Lower risk for alcohol- Bock HH, Lammert F. Nuclear xeno- Bruno R, Sacchi P, Filice G. Mitochondrial induced cirrhosis in wine drinkers. sensors as receptors for cholestatic bile toxicity in HIV-HCV coninfection: it 2002;35:868-875 acids: The second line of defense. depends on the choice of antiretroviral Bedin C (see Dubuisson L et al). 2002;35: 2002;35:232-234 (Hepatology drugs? 2002;35:500-501 325-331 Elsewhere) (Correspondence) Bedossa P (see Raynard B et al). 2002;35: Bodenheimer H (see Lok ASF et al). 2002; Brunt EM (see Kladney RD et al). 2002;35: 635-638 35:98 1-982 (Correspondence) 1431-1440 Belghiti J (see Fabre A et al). 2002;35:414- Bogdanos DP (see Ma Y et al). 2002;35: Budde K (see Preikschat P et al). 2002;35: 420 658-664 466-477 Bement W] (see Gorman N et al). 2002;35: Boitnott J (see Rai R et al). 2002;35:1247- Buelow R (see Amersi F et al). 2002;35: 912-921 1455 815-823 Benchimol D (see Baqué P et al). 2002;35: Bolognesi M, Sacerdoti D, Bombonato G, Buffet C (see Castéra L et al). 2002;35:978- 1144-1152 Merkel C, Sartori G, Merenda R, 979 (Correspondence) HEPATOLOGY, Vol. 35, No. 6, 2002 AUTHOR INDEX 1563 Bulla GA (see Kladney RD et al). 2002;35: Cavallo-Perin P (see Pagano G et al). 2002; Choi KS (see Park H-J et al). 2002;35: 1431-1440 35:367-372 1360-1371 Burda MR (see Dandri M et al). 2002;35: Cederbaum Al (see Nieto N et al). 2002; Chu C-J, Lok ASF. Clinical significance of 217-223 35:62-73 hepatitis B virus genotypes. 2002;35: Biirkle A (see Dandri M et al). 2002;35: — (see Wu D et al). 2002;35:1420-1430 1274-1276 (Editorial) 217-223 Cerliani JP (see de Lujan Alvarez M et al). Chu C-M (see Hsu Y-S et al). 2002;35: Busuttil RW (see Amersi F et al). 2002;35: 2002;35:824-833 1522-1527 815-823 Cerny A. Viral crosstalk: who gets to say Ciechanover A, Schwartz AL. Ubiquitin- Buti M, Sanchez-Avila F, Lurie Y, Stalgis what first? 2002;35:1540-1543 mediated degradation of cellular C, Valdés A, Martell M, Esteban R. (Hepatology Elsewhere) proteins in health and disease. 2002; Viral kinetics in genotype | chronic Cervantes F (see Perellé A et al). 2002;35: 35:3-6 (Science Frontier) hepatitis C patients during therapy 132-139 Clemens DL, Forman A, Jerrells TR, with 2 different doses of peginterferon Chaisson RE (see Sulkowski MS et al). Sorrell MF, Tuma DJ. Relationship alfa 2b plus ribavirin. 2002;35:930-936 2002;35:182-189 between acetaldehyde levels and cell Bzowej N (see Kato H et al). 2002;35:922- Chalasani N, Gorski JC, Patel NH, Hall survival in ethanol-metabolizing 929 SD, Galinsky RE. The effects of hepatoma cells. 2002;35:1196-1204 portal shunts on intestinal cytochrome Clemente G (see Salcedo M et al). 2002;35: 3A activity. 2002;35:1550-1551 c (Correspondence) Colecc3h4i9a- 3A5 6 (see Mazzella G et al). 2002; Chalasani N, Kahi C, Francois F, Pinto A, Caballeria L (see Boberg KM et al). 2002; 35:1291 (Correction) Marathe A, Bini EJ, Pandya P, ColmeneroJ (see FernandezJ et al). 2002; 35:652-657 Sitaraman S, Shen J. Model for end- Callejas NA, Casado M, Bosca L, Martin- 35:140-148 stage liver disease (MELD) for Sanz P. Absence of nuclear factor kB predicting mortality in patients with Conrad AJ (see Rosen HR et al). 2002;35: inhibition by NSAIDs in hepatocytes. 190-198 acute variceal bleeding. 2002;35: 2002;35:341-348 Cooper JT (see Arvelo MB et al). 2002;35: 1282-1284 Calvez V (see Thibault V et al). 2002;35: 535-543 Chang F-Y (see Huang Y-S et al). 2002;35: 238-239 (Correspondence) Coppel RL (see Matsumura S et al). 2002; 883-889 Calvisi DF (see Pascale RM et al). 2002;35: 35:14-22 Chang K-M (see Piasecki BA et al). 2002; 1341-1350 — (see Sasaki M et al). 2002;35:1284-1286 35:1538-1539 (Hepatology Elsewhere) Canela N (see Jaime M et al). 2002;35: (Correspondence) Chapman R (see Boberg KM et al). 2002; 1063-1071 Corpechot C, Barbu V, Wendum D, Cao J (see Mottino AD et al). 2002;35: 35:652-657 Kinnman N, Rey C, Poupon R, Chaput J-C (see Raynard B et al). 2002;35: 1409-1419 Housset C, Rosmorduc O. Hypoxia- 635-638 Capron F (see Raynard B et al). 2002;35: induced VEGF and collagen | Charlotte F (see Ratziu V et al). 2002;35: 635-638 expressions are associated with Carnovale C (see de Lujan Alvarez M et al). 1485-1493 angiogenesis and fibrogenesis in Charlton M, Sreekumar R, Rasmussen D, 2002;35:824-833 experimental cirrhosis. 2002;35:1010- Lindor K, Nair KS. Apolipoprotein Carpenter HA (see Czaja AJ et al). 2002;35: synthesis in nonalcoholic 1021 890-897 —, Poupon R. Promoter polymorphism of Carretero J (see Obrador E et al). 2002;35: steatohepatitis. 2002;35:898-904 the CD14 endotoxin receptor gene Chemin I (see Jeantet D et al). 2002;35: 74-81 and primary biliary cirrhosis. 2002; Carrillo MC (see de Lujan Alvarez M et al). 1215-1224 35:242-243 (Correspondence) Chen L (see Ansorena E et al). 2002;35: 2002;35:824-833 CostaJ (see Garcia-Retortillo M et al). Casabona D (see Pascale RM et al). 2002; 274-280 Chen W, Howell CD. Oligoclonal 2002;35:680-687 Casad3o5 :M1 34(s1e-e 1C3a5l0le jas NA et al). 2002;35: expansion of T cell receptor V beta 2 Costa RH (see Holterman A-XL et al). 341-348 and 3 cells in the livers of mice with 2002;35:1392-1399 Casanovas O (see Jaime M et al). 2002;35: graft-versus-host disease. 2002;35:23-29 — (see Tan Y et al). 2002;35:30-39 1063-1071 Chern H-D (see Huang Y-S et al). 2002; — (see Tan Y et al). 2002;35:790-798 Costagliola D (see Thibault V et al). 2002; Casciani CU (see Angelico M et al). 2002; 35:883-889 35:176-181 Chien R-N (see Hsu Y-S et al). 2002;35: 35:238-239 (Correspondence) Cassader M (see Pagano G et al). 2002;35: 1522-1527 Coulombel L (see Mallet VO et al). 2002; 367-372 Chiou H-Y (see Hsu Y-S et al). 2002;35: 35:799-804 Castéra L, Zigante F, Bastie A, Buffet C, 1522-1527 Crocenzi F (see Mottino AD et al). 2002; Dhumeaux D, Hardy P. Incidence of Chitturi S, Abeygunasekera S, Farrell GC, 35:1409-1419 interferon alfa—induced depression in Holmes-Walker J, Hui JM, Fung C, Cui X (see Kladney RD et al). 2002;35: patients with chronic hepatitis C. Karim R, Lin R, Samarasinghe D, 1431-1440 2002;35:978-979 (Correspondence) Liddle C, Weltman M, George J. Czaja AJ, Menon KVN, Carpenter HA. Cathomas G (see Helbling B et al). 2002; NASH and insulin resistance: insulin Sustained remission after 35:447-454 hypersecretion and specific association corticosteroid therapy for type Cauch-Dudek K (see Joshi S et al). 2002; with the insulin resistance syndrome. lautoimmune hepatitis: a 35:409-413 2002;35:373-379 retrospective analysis. 2002;35:890- Cavallaro L (see Ratziu V et al). 2002;35: Cho SY (see Park K-S et al). 2002;35:1459- 897 1485-1493 1466 — (see Liu H et al). 2002;35:772-778 Cavalli A (see Penna A et al). 2002;35: Choi K-H (see Park K-S et al). 2002;35: Czismadia E (see Arvelo MB et al). 2002; 1225-1236 1459-1466 35:535-543 1564 AUTHOR INDEX HEPATOLOGY, June 2002 Dent P (see Qiao L et al). 2002;35:779-789 Eisenstein RS (see Gorman N et al). 2002; — (see Rao Y-P et al). 2002;35:307-314 35:912-921 Dagan S (see Galun E et al). 2002;35:673- Depetris N (see Pagano G et al). 2002;35: Elia G (see Penna A et al). 2002;35:1225- 679 367-372 1236 — (see Galun E et al). 2002;35:986 Desmouliére A (see Dubuisson L et al). Elias E. Hepatology Highlights. 2002;35: (Correction) 2002;35:325-331 510-511, 1295-1296 Dagnelie PC (see Leij-Halfwerk S et al). Dhumeaux D (see Castéra L et al). 2002; Emerick KM, Whitington PF. Partial 2002;35:421-424 35:978-979 (Correspondence) external biliary diversion for Dahmen U (see Klugewitz K et al). 2002; Di Bisceglie AM, Bacon BR. Sample size in intractable pruritus and xanthomas in 35:568-578 trials of hepatitis C. 2002;35:500 Alagille syndrome. 2002;35:1501- Dalhoff K (see Schmidt LE et al). 2002;35: (Correspondence) 1506 876-882 —, McHutchison J, Rice CM. New Emi M (see Yasui K et al). 2002;35:1476- Dalton TP (see Gorman N et al). 2002;35: therapeutic strategies for hepatitis C. 1484 912-921 2002;35:224-231 (Special Article) Emile J-F (see Sebagh M et al). 2002;35: Dambach DM, Watson LM, Gray KR, Di Martino V (see Ratziu V et al). 2002;35: 117-125 Durham SK, Laskin DL. Role of 1485-1493 Eren R (see Galun E et al). 2002;35:673- CCR2 in macrophage migration into Di Paolo D (see Angelico M et al). 2002; 679 the liver during acetaminophen- 35:176-181 — (see Galun E et al). 2002;35:986 induced hepatotoxicity in the mouse. Diechi AM (see Younossi ZM et al). 2002; (Correction) 2002;35:1093-1103 35:746-752 (Perspectives in Clinical Escorsell A (see Perellé A et al). 2002;35: Dandri M, Burda MR, Biirkle A, Hepatology) 132-139 Zuckerman DM, Will H, Rogler CE, —. Liver regeneration in obese mice with —, Bafiares R, Garcia-Pagan JC, Gilabert Greten H, Petersen J. Increase in de fatty livers: does the impairment have R, Moitinho E, Piqueras B, Bru C, novo HBV DNA integrations in relevance for other types of fatty liver Echenagusia A, Granados A, Bosch J. response to oxidative DNA damage or disease? 2002;35:731-732 TIPS versus drug therapy in inhibition of poly(ADP-ribosyl)ation. (Correspondence) preventing variceal rebleeding in 2002;35:217-223 Dienes HP (see Dries V et al). 2002;35: advanced cirrhosis: a randomized Daniel S (see Arvelo MB et al). 2002;35: 1552-1553 (Correspondence) controlled trial. 2002;35:385-392 535-543 Dienstag JL (see McHutchison JG et al). Escudero A (see Mifiana JB et al). 2002;35: Date M (see Tahashi Y et al). 2002;35:49-61 2002;35:688-693 David E (see Pagano G et al). 2002;35:367- Doherty G (see Shimizu Y et al). 2002;35: 1205-1214 Esteban R (see Buti M et al). 2002;35:930- 372 805-814 Davis GL (see McHutchison JG et al). Dries V, Schirmacher P, Dienes HP, 936 Esteban-Mur R (see McHutchison JG et 2002;35:688-693 Gerken G, Bartenschlager R. Serum versus intrahepatic HCV RNA and al). 2002;35:688-693 De Diego A (see Salcedo M et al). 2002;35: Estrela JM (see Obrador E et al). 2002;35: 349-356 liver histology. 2002;35:1552-1553 (Correspondence) 74-81 de Groot H (see Kerkweg U et al). 2002; 35:560-567 Dubuisson L, Desmouliére A, Decourt B, Evade L (see Dubuisson L et al). 2002;35: De Groot PG (see Lisman T et al). 2002; Evadé L, Bedin C, Boussarie L, 325-331 35:616-621 Barrier L, Vidaud M, Rosenbaum Everhart JE, Yeh F, Lee ET, Hill MC, J. Inhibition of rat liver fibrogenesis Fabsitz R, Howard BV, Welty TK. de Knegt RJ (see Blokzijl H et al). 2002;35: 1551-1552 (Correspondence) through noradrenergic antagonism. Prevalence of gallbladder disease in De Luca M (see Solaun MS et al). 2002;35: 2002;35:325-331 American Indian populations: Dufour J-F (see Helbling B et al). 2002;35: findings from the Strong Heart Study. 1104-1116 de Lujan Alvarez M, Cerliani JP, Monti J, 447-454 2002;35:1507-1512 Carnovale C, Ronco MT, Pisani G, — (see Redaelli CA et al). 2002;35:1082- Lugano MC, Carrillo MC. The in 1092 F vive apoptotic effect of interferon alfa- Duner E (see Melero S et al). 2002;35: 2b on rat preneoplastic liver involves 1513-1521 Faber KN (see Plass JRM et al). 2002;35: Bax protein. 2002;35;:824-833 Durham SK (see Dambach DM et al). 589-596 De Miglio MR (see Pascale RM et al). 2002;35:1093-1103 Fabre A, Audet P, Vilgrain V, Nguyen BN, 2002;35:1341-1350 Diirr R (see Ma Y et al). 2002;35:658-664 Valla D, Belghiti J, Degott C. Debonera F (see Aldeguer X et al). 2002; Dvorchik I, Subotin M, Demetris AJ, Fung Histologic scoring of liver biopsy in 35:40-48 JKJM, .S taErzflf ecTtE ,o f lWiiveera ndt raSn,s pAlbanut-aEtliomna godn focal nodular hyperplasia with atypical Decourt B (see Dubuisson L et al). 2002; presentation. 2002;35:414-420 inflammatory bowel disease in 35:325-331 Fabre M (see Mallet VO et al). 2002;35: patients with primary sclerosing Degott C (see Fabre A et al). 2002;35:414-420 799-804 Del Bene R (see La Villa G et al). 2002;35: cholangitis. 2002;35:380-384 Fabregat I (see Pafieda C et al). 2002;35: 1441-1448 1381-1391 Del Olmo J (see Mifiana JB et al). 2002;35: Fabsitz R (see Everhart JE et al). 2002;35: 1205-1214 1507-1512 Delaugerre C (see Thibault V et al). 2002; Echenagusia A (see Escorsell A et al). 2002; Falissard B (see Sebagh M et al). 2002;35: 35:238-239 (Correspondence) 35:385-392 117-125 Demetris AJ (see Dvorchik | et al). 2002; Egeland T (see Boberg KM et al). 2002;35: Fallik D (see Raynard B et al). 2002;35: 35:380-384 652-657 635-638 Denk H (see Stumptner C et al). 2002;35: Eguchi K (see Abiru S et al). 2002;35:1117- Fan S-T (see Lo C-M et al). 2002;35:1164- 1053-1062 1124 1171 HEPATOLOGY, Vol. 35, No. 6, 2002 AUTHOR INDEX 1565 Fantappié O, Masini E, Sardi I, Raimondi Fouchard-Hubert I (see Gergely AE et al). Garcia-Pagan JC (see Escorsell A et al). L, Bani D, Solazzo M, Vannacci A, 2002;35:1281-1282 2002;35:385-392 Mazzanti R. The MDR phenotype is (Correspondence) — (see Perellé A et al). 2002;35:132-139 associated with the expression of Francis H (see Alpini G et al). 2002;35: Garcia-Retortillo M, Forns X, Feliu A, COX-2 and iNOS in a human 1041-1052 Moitinho E, Costa J, Navasa M, hepatocellular carcinoma cell line. — (see Kanno N et al). 2002;35:1329- Rimola A, Rodes J. Hepatitis C virus 2002;35:843-852 1340 kinetics during and immediately after Farrell GC (see Chitturi S et al). 2002;35: Francois F (see Chalasani N et al). 2002;35: liver transplantation. 2002;35:680- 373-379 1282-1284 687 Farrell GC, Robertson GR, Leclercq I, Frau M (see Pascale RM et al). 2002;35: Garcia-Trevijano ER (see Ansorena E et al). Horsmans Y. Liver regeneration in 1341-1350 2002;35:274-280 obese mice with fatty livers: does the Frese M, Schwarzle V, Barth K, Krieger N, Gatta A (see Bolognesi M et al). 2002;35: impairment have relevance for other Lohmann V, Mihm S, Haller O, 601-608 types of fatty liver disease? 2002;35: Bartenschlager R. Interferon-y Gavelli A (see Baqué P et al). 2002;35: 731 (Correspondence) inhibits replication of subgenomic 1144-1152 Feliu A (see Garcia-Retortillo M et al). and genomic hepatitis C virus RNAs. Gelman AE (see Aldeguer X et al). 2002;35: 2002;35:680-687 2002;35:694-703 40-48 Feltracco P (see Bolognesi M et al). 2002; Friedman SL (see Adachi S et al). 2002;35: Gentilini P (see La Villa G et al). 2002;35: 35:601-608 332-340 1441-1448 Feo F (see Pascale RM et al). 2002;35: — (see Nieto N et al). 2002;35:62-73 GeorgeJ (see Chitturi S et al). 2002;35: 1341-1350 — (see Saxena NK et al). 2002;35:762-771 373-379 Ferenci P, Lockwood A, Mullen K, Tarter Fuchs M, Ivandic B, Mueller O, Schalla C, George JW (see Bourdi M et al). 2002;35: R, Weissenborn K, Blei AT, Members Scheibner J, Bartsch P, Stange EF. 289-298 of the Working Party. Hepatic HDL receptor SR-BI and cholesterol Gerbes AL (see Giilberg V et al). 2002;35: encephalopathy— definition, gallstones. 2002;35:241-242 630-634 nomenclature, diagnosis, and (Correspondence) — (see Kiemer AK et al). 2002;35:88-94 quantification: final report of the Fuchsbichler A (see Stumptner C et al). Gergely AE, Lafarge P, Fouchard-Hubert I, working party at the 11th World 2002;35:1053-1062 Lunel-Fabiani F. Treatment of Congresses of Gastroeneterology, Fujie H (see Tsutsumi T et al). 2002;35: ribavirin/interferon-induced anemia Vienna, 1998. 2002;35:716-721 937-946 with erythropoietin in patients with (Special Article) Fukada K (see Imai Y et al). 2002;35:974- hepatitis C. 2002;35:1281-1282 Fernandez J, Navasa M, Gémez J, 976 (Correspondence) (Correspondence) Colmenero J, Vila J, Arroyo V, Rodés Fukui H (see Yoshiji H et al). 2002;35:834- Gerhard GS (see Gorman N et al). 2002; J. Bacterial infections in cirrhosis: 842 35:912-921 Epidemiological changes with invasive Fung C (see Chitturi S et al). 2002;35:373- Gerken G (see Dries V et al). 2002;35: procedures and norfloxacin 379 1552-1553 (Correspondence) prophylaxis. 2002;35:140-148 Fung JJ (see Dvorchik I et al). 2002;35: Gerner C (see Grasl-Kraupp B et al). 2002; Ferran C (see Arvelo MB et al). 2002;35: 380-384 35:1372-1380 535-543 Furukawa F (see Tahashi Y et al). 2002;35: Gershwen ME (see Sasaki M et al). 2002; Ferrari C (see Penna A et al). 2002;35: 49-61 35:1284-1286 (Correspondence) 1225-1236 Fushimi K (see Ninomiya T et al). 2002; — (see Matsumura §S et al). 2002;35:14-22 Ferry N (see Auvigne | et al). 2002;35:281- 35:82-87 Geuken M (see Plass JRM et al). 2002;35: 288 589-596 Festi D (see Mazzella G et al). 2002;35: Gil G (see Pandak WM et al). 2002;35: 1291 (Correction) 1400-1408 Filice G (see Bruno R et al). 2002;35:500- Gilabert R (see Escorsell A et al). 2002;35: 501 (Correspondence) Galinsky RE (see Chalasani N et al). 2002; 385-392 Fimmel C] (see Kladney RD et al). 2002; 35:1550-1551 (Correspondence) — (see Perellé A et al). 2002;35:132-139 35°1431-1440 Galun E, Eren R, Safadi R, Ashour Y, Gilat T, Leiken-Frenkel A, Goldiner I, Flemming P (see Kleeberger W et al). 2002; Terrault N, Keeffe EB, Matot E, Halpern Z, Konikoff FM. Dissolution 35:110-116 Mizrachi S, Terkieltaub D, Zohar M, of cholesterol gallstones in mice by the Flye MW (see Shimizu Y et al). 2002;35: Lubin I, Gopher J, Shouval D, Dagan oral administration of a fatty acid bile 805-814 S. Clinical evaluation (phase I) of a acid conjugate. 2002;35:597-600 Forlani G (see Marchesini G et al). 2002; combination of two human monoclonal Gilgenkrantz H (see Mallet VO et al). 35:497-499 (Editorial) antibodies to HBV: safety and antiviral 2002;35:799-804 Forman A (see Clemens DL et al). 2002;35: properties. 2002;35:673-679 Giostra E (see Latorre P et al). 2002;35: 1196-1204 —. Clinical evaluagion (phase I) ofa 239-240 (Correspondence) Forns X (see Garcia-Retortillo M et al). combination of two human Giral P (see Ratziu V et al). 2002;35:1485- 2002;35:680-687 monoclonal antibodies to HBV: safety 1493 Forton DM, Thomas HC, Murphy CA, and antiviral properties. 2002;35:986 Gish RG (see Kato H et al). 2002;35:922- Allsop JM, Foster GR, Main J, (Correction) 929 Wesnes KA, Taylor-Robinson SD. Gambino R (see Pagano G et al). 2002;35: Glaser S (see Alpini G et al). 2002;35:1041- Hepatitis C and cognitive impairment 367-372 1052 in a cohort of patients with mild liver Gao B (see Nguyen V-A et al). 2002;35: — (see Kanno N et al). 2002;35:1329- disease. 2002;35:433-439 425-432 1340 Foster GR (see Forton DM et al). 2002;35: Garaud JJ (see McHutchison JG et al). Glickman JN (see Baify G et al). 2002;35: 433-439 2002;35:688-693 753-761 1566 AUTHOR INDEX HEPATOLOGY, June 2002 Gléckner S (see Kleeberger W et al). 2002; Gronbak M (see Becker U et al). 2002;35: Heathcote EJ (see Joshi S et al). 2002;35: 35:110-116 868-875 409-413 Goldiner | (see Gilat T et al). 2002;35:597- Gross JB. Sample size in trials of hepatitis —. Personal reminiscences: Sheila 600 C. 2002;35:500 (Correspondence) Sherlock. 2002;35:1536-1537 Gomez J (see FernandezJ et al). 2002;35: Groszmann RJ (see Wiest R et al). 2002;35: (Special Article) 140-148 478-491 (Special Article) HeegsmaJ (see Plass JRM et al). 2002;35: Gémez-Cambronero L (see Mifiana JB et Guicciardi ME (see Nzeako UC et al). 589-596 al). 2002;35:1205-1214 2002;35:552-559 Heid H (see Stumptner C et al). 2002;35: Gonvers J-) (see Helbling B et al). 2002;35: —, Gores GJ. Ursodeoxycholic acid 1053-1062 447-454 cytoprotection: dancing with death Heidrich B (see HerkelJ et al). 2002;35: Gonzalez M (see Bafiares R et al). 2002;35: receptors and survival pathways. 403-408 609-615 2002;35:97 1-973 (Editorial) Helbling B, Stamenic I, Viani F, Gonvers Goodman ZD (see McHutchison JG et al). Guidotti J-E (see Mallet VO et al). 2002; J-J, Dufour J-F, Reichen J, Cathomas 2002;35:688-693 35:799-804 G, Steuerwald M, Borovicka J, Gopher J (see Galun E et al). 2002;35:673- Giilberg V, Haag K, Réssle M, Gerbes AL. Sagmeister M, Renner EL, 679 Hepatic arterial buffer response in Investigators of the Swiss Association — (see Galun E et al). 2002;35:986 patients with advanced cirrhosis. for the Study oft he Liver. Interferon (Correction) 2002;35:630-634 and amantadine in naive chronic Gores G] (see Guicciardi ME et al). 2002; Gunther S (see Preikschat P et al). 2002;35: hepatitis C A double-blind, 35:97 1-973 466-477 randomized placebo-controlled trial. — (see Nzeako UC et al). 2002;35:552-559 Gupta S (see Qiao L et al). 2002;35:779- 2002;35:447-454 Gorman N, Ross KL, Walton HS, Bement 789 Heneghan MA, McFarlane IG. Current WJ, Szakacs JG, Gerhard GS, Dalton — (see Rao Y-P et al). 2002;35:307-314 and novel immunosuppressive therapy TP, Nebert DW, Eisenstein RS, — (see Slehria S et al). 2002;35:1320-1328 for autoimmune hepatitis. 2002;35:7- Sinclair JF, Sinclair PR. Uroporphyria Gutierrez V (see Solaun MS et al). 2002;35: 13 (Perspective in Clinical in mice: thresholds for hepatic 1104-1116 Hepatology) CYP1A2 and iron. 2002;35:912-921 Herkel J, Heidrich B, Nieraad N, Wies I, Gorospe I (see Pafieda C et al). 2002;35: Rother M, Lohse AW. Fine specificity 1381-1391 of autoantibodies to soluble liver Gorski JC (see Chalasani N et al). 2002;35: Haag K (see Giilberg V et al). 2002;35:630- antigen and liver/pancreas. 2002;35: 1550-1551 (Correspondence) 634 403-408 Gosert R, Moradpour D. A new twist to Hafner MS (see Woodcroft KJ et al). 2002; Hernandez-Albujar A (see Salcedo M et al). translation initiation of the hepatitis 35:263-273 2002;35:349-356 C virus. 2002;35:724-726 Hagenbuch B (see Kullak-Ublick GA et al). Herrera B (see Pafieda C et al). 2002;35: (Hepatology Elsewhere) 2002;35:732-733 (Correspondence) 1381-1391 Gotwals P (see Yata Y et al). 2002;35:1022- Hall SD (see Chalasani N et al). 2002;35: Hicklin DJ (see Yoshiji H et al). 2002;35: 1030 1550-1551 (Correspondence) 834-842 Gouma DJ (see Sewnath ME et al). 2002; Hill MC (see Everhart JE et al). 2002;35: Haller O (see Frese M et al). 2002;35:694- 35:149-158 703 1507-15$12 GrafJ (see Zsembery A et al). 2002;35:95- Halpern Z (see Gilat T et al). 2002;35:597- Hilsabeck RC, Perry W, Hassanein TI. 104 600 Neuropsychological impairment in Granados A (see Escorsell A et al). 2002;35: patients with chronic hepatitis C. Hamann A (see Klugewitz K et al). 2002; 385-392 35:568-578 2002;35:440-446 Grant S (see Qiao L et al). 2002;35:779- Hamasaki K (see Abiru S et al). 2002;35: Himeno Y (see Tahashi Y et al). 2002;35: 789 ‘ 1117-1124 49-61 Grasl-Kraupp B, Schausberger E, Hufnagl Hammerman C (see Kaplan M et al). 2002; Hinrichs D] (see Rosen HR et al). 2002;35: K, Gerner C, Léw-Baselli A, 35:905-911 190-198 Rossmanith W, Parzefall W, Schulte- Hara M (see Moritmoto M et al). 2002;35: Hiroyasu S (see Aldeguer X et al). 2002;35: Hermann R. A novel mechanism for 1467-1475 40-48 mitogenic signaling via Hardy P (see Castéra L et al). 2002;35:978- Hirsch-Ernst KI (see Ziemann C et al). pro—transforming growth factor a 979 (Correspondence) 2002;35:579-588 within hepatocyte nuclei. 2002;35: Harvey J (see McHutchison JG et al). 2002; Hofmann AF (see Meng L-J et al). 2002; 1372-1380 35:688-693 35:1031-1040 Gray KR (see Dambach DM et al). 2002; Hashimoto N (see Shibuya A et al). 2002; Holmes-Walker J (see Chitturi S et al). 35:1093-1103 35:1172-1178 2002;35:373-379 Green J (see Bernstein D et al). 2002;35: Hashimoto-Tamaoki T (see Ninomiya T et Holterman A-XL, Tan Y, Kim W, Yoo 704-708 al). 2002;35:82-87 KW, Costa RH. Diminished hepatic Greten H (see Dandri M et al). 2002;35: Hassanein TI (see Hilsabeck RC et al). expression of theN HF-6 transcription 217-223 2002;35:440-446 factor during bile duct obstruction. Grey ST (see Arvelo MB et al). 2002;35: Haussinger D (see Kircheis G et al). 2002; 2002;35:1392-1399 535-543 35:357-366 Honda M (see Shimazaki T et al). 2002;35: Griffiths J, Nix B. Modeling the hepatitis Havinga R (see Plésch T et al). 2002;35: 199-208 C virus epidemic in France using the 299-306 Hong Z (see Lau JYN et al). 2002;35:1002- temporal pattern of hepatocellular Hayashi Y (see Ninomiya T et al). 2002;35: 1009 (Perspectives in Clinical carcinoma deaths. 2002;35:709-715 82-87 Hepatology) Grimaldi A (see Ratziu V et al). 2002;35: He X-S (see Sasaki M et al). 2002;35:1284- Hopf U (see Steinmiiller T et al). 2002;35: 1485-1493 1286 (Correspondence) 1528-1535 HEPATOLOGY, Vol. 35, No. 6, 2002 AUTHOR INDEX 1567 Horie T (see Masubuchi Y et al). 2002;35: llic Z (see Yin L et al). 2002;35:315-324 antigen—negative patient. 2002;35: 544-551 Imai Y, Ohsawa M, Tanaka H, Tamura S, 1215-1224 Horsmans Y (see Farrell GC et al). 2002; Sugawara H, Kuyama J, Fukada K, Jeng K-S (see Hsu S-C et al). 2002;35:665- 35:731 (Correspondence) Yonezawa T, Matszawa Y. High 672 Housset C (see Corpechot C et al). 2002; prevalence of HCV infection in Jerrells TR (see Clemens DL et al). 2002; 35:1010-1021 patients with B-cell non-Hodgkin’s 35:1196-1204 Howard BV (see Everhart JE et al). 2002; lymphoma: comparison with birth Jessner W (see Zsembery A et al). 2002;35: 35:1507-1512 cohort—and sex-matched blood donors 95-104 Howell CD (see Chen W et al). 2002;35: in a Japanese population. 2002;35: Jilg W (see Bauer T et al). 2002;35:455- 23-29 974-976 (Correspondence) 465 Hsu S-C, Syu W-J, Sheen I-J, Liu H-T, Imazu H (see Yoshiji H et al). 2002;35: Jirtle RL (see Oka Y et al). 2002;35:1153- Jeng K-S, Wu J-C. Varied assembly 834-842 1163 and RNA editing efficiencies between Imada T (see Moritmoto M et al). 2002;35: Johansen D (see Becker U et al). 2002;35: genotypes | and II hepatitis D virus 1467-1475 868-875 and their implications. 2002;35:665- Imoto I (see Yasui K et al). 2002;35:1476- Jonas S (see Steinmiiller T et al). 2002;35: 672 1484 1528-1535 Hsu Y-S, Chien R-N, Yeh C-T, Sheen I-S, Inagaki Y (see Tahashi Y et al). 2002;35:49- Jones EA, Lavini C. Is cerebral edema a Chiou H-Y, Chu C-M, Liaw Y-F. 61 component of the syndrome of Long-term outcome after spontaneous InazawaJ (see Yasui K et al). 2002;35: hepatic encephalopathy? 2002;35: HBeAg seroconversion in patients 1476-1484 1270-1273 (Hepatology Eewhere) with chronic hepatitis B. 2002;35: Inoue K (see Tahashi Y et al). 2002;35:49- —. Rationale for trials of long-term 1522-1527 61 mycophenolate mofetil therapy for Huang L (see Liu F et al). 2002;35:1314- International Hepatitis Interventional primary biliary cirrhosis. 2002;35: 1319 Therapy Group (see McHutchison JG 258-262 (Perspective in Clinical Huang Y-S, Chern H-D, Su W-J, Wu J-C, et al). 2002;35:688-693 Hepatology) Lai S-L, Yang S-Y, Chang F-Y, Lee Iraburu M (see Ansorena E et al). 2002;35: Jones H (see Ujhazy P et al). 2002;35:246 S-D. Polymorphism of the N- 274-280 (Correction) acetyltransferase 2 gene as a Ishikawa H (see Abiru S et al). 2002;35: Jones MK (see Kawanaka H et al). 2002;35: susceptibility risk factor for 1117-1124 393-402 antituberculosis drug-induced Ito H (see Shiota G et al). 2002;35:1125- Joplin RE (see Melero S et al). 2002;35: hepatitis. 2002;35:883-889 1133 1513-1521 Huang Z-Z (see Ansorena E et al). 2002; Ito Y (see Slehria S et al). 2002;35:1320- Jorgensen R (see Joshi S et al). 2002;35: 35:274-280 1328 409-413 HuberJ (see Yoshiji H et al). 2002;35:834- Ivandic B (see Fuchs M et al). 2002;35: Joshi S$, Cauch-Dudek K, Wanless IR, 842 241-242 (Correspondence) Lindor KD, Jorgensen R, Batts K, Hubscher SG (see Neil DAH et al). 2002; Iwashita A (see Oka Y et al). 2002;35:1153- Heathcote EJ. Primary biliary 35:639-651 1163 cirrhosis with additional features of Huehnergarth KV (see Raaka S et al). 2002; lyer S (see Amersi F et al). 2002;35:815- autoimmune hepatitis: response to 35:977-978 (Correspondence) 823 therapy with ursodeoxycholic acid. Hufnagl K (see Grasl-Kraupp B et al). 2002;35:409-413 2002;35:1372-1380 Jung D (see Kullak-Ublick GA et al). 2002; Hughes D (see Tan Y et al). 2002;35:30-39 J 35:732-733 (Correspondence) Hui JM (see Chitturi § et al). 2002;35:373- Jaeschke H. Inflammation in response to 379 hepatocellular apoptosis. 2002;35: Hultcrantz R (see Boberg KM et al). 2002; 964-966 (Hepatology Elsewhere) 35:652-657 Jaime M, Pujol MJ, Serratosa J, Pantoja C, Kahi C (see Chalasani N et al). 2002;35: Hylemon PB (see Pandak WM et al). 2002; Canela N, Casanovas O, Serrano M, 1282-1284 35:1400-1408 Hylemon PB (see Qiao L et al). 2002;35: Agell N, Bachs O. The p21“?! Kahl GF (see Ziemann C et al). 2002;35: protein, a cyclin inhibitor, regulates 579-588 779-789 the levels and the intracellular Kahn A (see Mallet VO et al). 2002;35: — (see Rao Y-P et al). 2002;35:307-314 localization of CDC25A in mice 799-804 regenerating livers. 2002;35:1063-1071 — (see Tannour-Louet M et al). 2002;35: Jalan R (see Sen S et al). 2002;35:1269 107° ‘081 Jang H-S (see Oka Y et al). 2002;35:1153- Kaiser T (see Klugewitz K et al). 2002;35: Ichikawa T (see Abiru S et al). 2002;35: 1163 568-578 1117-1124 Jansen PLM (see Plass JRM et al). 2002;35: Kamiya A, Kojima N, Kinoshita T, Sakai Ijichi M, Takayama T, Matsumura M, 589-596 Y, Miyaijma A. Maturation of fetal Shiratori Y, Omata M, Makuuchi M. — PLM (see Plésch T et al). 2002;35:299- hepatocytes in vitro by extracellular a-fetoprotein mRNA in the 306 matrices and oncostatin M: induction circulation as a predictor of —, Miiller M, Sturm E. Organic anion of tryptophan oxygenase. 2002;35: postsurgical recurrence of transporting polypeptides, cholestasis, 1351-1359 hepatocellular carcinoma: a and nuclear receptors. 2002;35:733- Kaneko S (see Shimazaki T et al). 2002;35: prospective study. 2002;35:853-860 734 (Correspondence) 199-208 Ikeda K (see Saxena NK et al). 2002;35: Jeantet D, Chemin I, Mandrand B, Zoulim Kanno N, LeSage G, Phinizy JL, Glaser S, 762-771 F, Trepo C, Kay A. Characterization Francis H, Alpini G. Stimulation of Ikenaka Y (see Yoshiji H et al). 2002;35: of two hepatitis B virus populations a-adrenergic receptor inhibits 834-842 isolated from a hepatitis B surface cholangiocarcinoma growth through 1568 AUTHOR INDEX HEPATOLOGY, June 2002 modulation of Raf-1 and B-raf Kim S-] (see Park H-J et al). 2002;35:1360- Kruger DH (see Preikschat P et al). 2002; activities. 2002;35:1329-1340 1371 35:466-477 Kaplan M, Hammerman C, Rubaltelli Kim W (see Holterman A-XL et al). 2002; Ku N-O (see Omary MB et al). 2002;35: FF, Vilei MT, Levy-Lahad E, 35:1392-1399 251-257 (Concise Review) Renbaum P, Vreman HJ, Stevenson Kinnman N (see Corpechot C et al). 2002; Kuipers F (see Plésch T et al). 2002;35: DK, Muraca M. Hemolysis and 35:1010-1021 299-306 bilirubin conjugation in association Kinoshita T (see Kamiya A et a!}. 2002;35: Kullak-Ublick GA, Jung D, Hagenbuch B, with UDP-glucuronosyltransferase 1351-1359 Meier PJ. Organic anion transporting 1A1 promoter polymorphism. 2002; Kircheis G, Wettstein M, Timmermann L, polypeptides, cholestasis, and nuclear 35:905-911 Schnitzler A, Haussinger D. Critical receptors. 2002;35:732-733 Kaplowitz N. Hepatology Highlights. flicker frequency for quantification of (Correspondence) 2002;35:249-250, 991-992 low-grade hepatic encephalopathy. Kupiec-Weglinski JW (see Amersi F et al). Karim R (see Chitturi S et al). 2002;35: 2002;35:357-366 2002;35:8 15-823 373-379 Kishimoto Y (see Shiota G et al). 2002;35: Kuriyama S (see Yoshiji H et al). 2002;35: Katlama C (see Thibault V et al). 2002;35: 1125-1133 834-842 238-239 (Correspondence) Kita H (see Matsumura S et al). 2002;35: Kury E (see Klugewitz K et al). 2002;35: Kato H, Orito E, Gish RG, Bzowej N, 14-22 568-578 Newsom M, Sugauchi F, Suzuki S, Kiyosawa K (see Umemura T et al). 2002; Kuyama J (see Imai Y et al). 2002;35:974- Ueda R, Miyakawa Y, Mizokami M. 35:953-959 976 (Correspondence) Hepatitis B ¢ antigen in sera from Kladney RD, Cui X, Bulla GA, Brunt EM, individuals infected with hepatitis B Fimmel CJ. Expression of GP73, a virus of the genotype G. 2002;35: resident Golgi membrane protein, in L 922-929 viral and nonviral liver disease. 2002; Katori M (see Amersi F et al). 2002;35: 35:1431-1440 La Villa G, Barletta G, Romanelli RG, 815-823 Kleeberger W, Rothimel T, Gléckner S, Lafh G, Del Bene R, Vizzutti F, Kawanaka H, Jones MK, Szabo IL, Baatar Flemming P, Lehmann U, Kreipe H. Pantaleo P, Mazzocchi V, Gentilini P. High frequency of epithelial Cardiovascular effects of canrenone in D, Pai R, Tsugawa K, Sugimachi K, Sarfeh I], Tarnawski AS. Activation of chimerism in liver transplants patients with preascitic cirrhosis. demonstrated by microdissection and 2002;35:1441-1448 eNOS in rat portal hypertensive gastric mucosa is mediated by TNF-a STR-analysis. 2002;35:110-116 Lafarge P (see Gergely AE et al). 2002;35: via the PI 3-kinase—Akt signaling Kleinman L (see Bernstein D et al). 2002; 1281-1282 (Correspondence) pathway. 2002;35:393-402 35:704-708 Lafhi G (see La Villa G et al). 2002;35: Klugewitz K, Topp SA, Dahmen U, Kaiser 1441-1448 Kawasaki H (see Shiota G et al). 2002;35: T, Sommer S, Kury E, Hamann A. Lai S-L (see Huang Y-S et al). 2002;35: 1125-1133 Differentiation-dependent and subset- 883-889 Kay A (see Jeantet D et al). 2002;35:1215- specific recruitment of T-helper cells Lam C-M (see Lo C-M et al). 2002;35: 1224 into murine liver. 2002;35:568-578 1164-1171 Keeffe EB (see Galun E et al). 2002;35: Kobayashi K (see Shimazaki T et al). 2002; Lammert F (see Bock HH et al). 2002;35: 673-679 35:199-208 232-234 (Hepatology Elsewhere) — (see Galun E et al). 2002;35:986 Kéck | (see von Weizsicker F et al). 2002; Lamonaca V (see Penna A et al). 2002;35: (Correction) 35:209-216 1225-1236 Kelley-Loughnane N, Sabla GE, Ley-Ebert Koike K (see Tsutsumi T et al). 2002;35: Landeros K (see Shimizu Y et al). 2002;35: C, Aronow BJ, Bezerra JA. 937-946 805-814 Independent and overlapping Kojima N (see Kamiya A et al). 2002;35: LaRusso NF (see Alpini G et al). 2002;35: transcriptional activation during liver 1351-1359 1256-1268 (Special Article) development and regeneration in Kojima S (see Adachi § et al). 2002;35:332- Laskin DL (see Dambach DM et al). 2002; mice. 2002;35:525-534 340 35:1093-1103 Kerkweg U, Li T, de Groot H, Rauen U. Kokawa A (see Moritmoto M et al). 2002; Latorre P, Rubbia-Brandt L, Giostra E, Cold-induced apoptosis of rat liver 35:1467-1475 Abid K, Negro F. The 4,977—base cells in University of Wisconsin Komatsu T (see Shibuya A et al). 2002;35: pair common deletion of solution: the central role of chelatable 1172-1178 mitochondrial DNA is not associated iron. 2002;35:560-567 Konikoff FM (see Gilat T et al). 2002;35: with steatosis in chronic hepatitis C Kiemer AK, Gerbes AL, Bilzer M, Vollmar 597-600 patients. 2002;35:239-240 AM. The atrial natriuretic peptide Koteliansky V (see Yata Y et al). 2002;35: (€ Sorrespondence) and cGMP: novel activators of the 1022-1030 Lau JYN, Tam RC, Liang TJ, Hong Z. heat shock response in rat livers. Kovalovich KK (see Aldeguer X et al). Mechanism of action of ribavirin in 2002;35:88-94 2002;35:40-48 the combination treatment of chronic Killian JK (see Oka Y et al). 2002;35:1153- Kowdley KV (see Raaka S et al). 2002;35: HCY infection. 2002;35:1002-1009 1163 977-978 (€ ‘orrespondence) (Perspectives in Clinical Hepatology) Kim B-C (see Park H-] et al). 2002;35: Krasinkas AM (see Aldeguer X et al). 2002; Lautt WW (see Ming Z et al). 2002;35: 1360-1371 35:40-48 167-175 Kim H (see Park K-S et al). 2002;35:1459- Kreipe H (see Kleeberger W et al). 2002;35: Lavini C (see Jones EA et al). 2002;35: 1466 110-116 1270-1273 (Hepatology Elsewhere) Kim N-G (see Park K-S et al). 2002;35: Kren BT (see Richardson PD et al). 2002; Layden JE, Layden TJ. Viral kinetics of 1459-1466 35:512-518 (Science Frontier) hepatitis C: new insights and Kim RB (see Meng L-] et al). 2002;35: Krieger N (see Frese M et al). 2002;35:694- remaining limitations. 2002;35:967- 1031-1040 703 970 (Editorial) HEPATOLOGY, Vol. 35, No. 6, 2002 AUTHOR INDEX _ 1569 Layden TJ (see Layden JE et al). 2002;35: Ling M-H (see McHutchison JG et al). — (see Galun E et al). 2002;35:986 967-970 (Editorial) 2002;35:688-693 (Correction) Leclercq I (see Farrell GC et al). 2002;35: Lionetti R (see Angelico M et al). 2002;35: Lugano MC (see de Lujan Alvarez M et al). 731 (Letter) 176-181 2002;35:824-833 Ledermann M (see Redaelli CA et al). Lisman T, Leebeek FWG, Meijer K, Van Lunel-Fabiani F (see Gergely AE et al). 2002;35:1082-1092 Der Meer J, Nieuwenhuis HK, De 2002;35:1281-1282 Lee ET (see Everhart JE et al). 2002;35: Groot PG. Recombinant factor VIIa (Correspondence) 1507-1512 improves clot formulation but not Lurie Y (see Buti M et al). 2002;35:930- Lee J-S, Thorgeirsson SS. “unctional and fibrinolytic potential in patients with 936 genomic implications of global gene cirrhosis and during liver expression profiles in cell lines from transplantation. 2002;35:616-621 human hepatocellular cancer. 2002; Liu C-L (see Lo C-M et al). 2002;35:1164- 35:1134-1143 1171 Ma Y, Okamoto M, Thomas MG, Lee S-D (see Huang Y-S et al). 2002;35: Liu F, Huang L. Noninvasive gene delivery Bogdanos DP, Lopes AR, Portmann 883-889 to the liver by mechanical massage. B, Underhill J, Diirr R, Mieli-Vergani Lee SS (see Song D et al). 2002;35:159-166 2002;35:1314-1319 G, Vergani D. Antibodies to Leebeek FWG (see Lisman T et al). 2002; Liu H (see Song D et al). 2002;35:159-166 conformational epitopes of soluble 35:616-621 —, Lo CR, Czaja MJ. NF-«B inhibition liver antigen define a severe form of Leffert HL (see Yin L et al). 2002;35:315- sensitizes hepatocytes to TNF- autoimmune liver disease. 2002;35: 324 induced apoptosis through a sustained 658-664 Lehmann U (see Kleeberger W et al). 2002; activation of JNK and c-Jun. 2002; Maeta Y (see Shiota G et al). 2002;35: 35:110-116 35:772-778 1125-1133 Leij-Halfwerk S, Agteresch HJ, Sijens PE, Liu H-T (see Hsu S-C et al). 2002;35:665- MahiouJ (see Arvelo MB et al). 2002;35: Dagnelie PC. Adenosine triphosphate 672 535-543 infusion increases liver energy status Liu P (see Wong F et al). 2002;35:1449- MainJ (see Forton DM et al). 2002;35: in advanced lung cancer patients: an 1458 433-439 in vivo *'P magnetic resonance Lloret A (see Mifiana JB et al). 2002;35: Makuuchi M (see Ijichi M et al). 2002;35: spectroscopy study. 2002;35:421-424 1205-1214 853-860 Leiken-Frenkel A (see Gilat T et al). 2002; Llovet JM (see BruixJ et al). 2002;35:519- Mallet VO, Mitchell C, Mezey E, Fabre 35:597-600 524 (Perspectives in Clinical M, Guidotti J-E, Renia L, Coulombel Lemon SM (see Li K et al). 2002;35:1237- Hepatology) L, Kahn A, Gilgenkrantz H. Bone 1246 Lo C-M, Ngan H, Tso W-K, Liu C-L, marrow transplantation in mice leads LeSage G (see Alpini G et al). 2002;35: Lam C-M, Poon RT-P, Fan S-T, to a minor population of hepatocytes 1041-1052 Wong J. Randomized controlled trial that can be selectively amplified in — (see Kanno N et al). 2002;35:1329- of transarterial lipiodol vivo. 2002;35:799-804 1340 chemoembolization for unresectable Mallonee D (see Pandak WM et al). 2002; Levy-Lahad E (see Kaplan M et al). 2002; hepatocellular carcinoma. 2002;35: 35:1400-1408 35:905-911 1164-1171 Mandrand B (see Jeantet D et al). 2002;35: Lewinsohn DM (see Rosen HR et al). Lo CR (see Liu H et al). 2002;35:772-778 1215-1224 2002;35:190-198 Lockwood A (see Ferenci P et al). 2002;35: Manns MP (see Vogel A et al). 2002;35: Ley-Ebert C (see Kelley-Loughnane N et 716-721 (Special Article) 126-131 al). 2002;35:525-534 Lohmann V (see Frese M et al). 2002;35: Maor-Kendler Y (see Angulo P et al). 2002; Li K, Prow T, Lemon SM, Beard MR. 694-703 35:1494-1500 Cellular response to conditional Lohse AW (see Herkel J et al). 2002;35: Marathe A (see Chalasani N et al). 2002; expression of hepatitis C virus core 403-408 35:1282-1284 protein in Huh7 cultured human Lok ASF (see Chu C-J et al). 2002;35: Marchesini G, Forlani G. NASH: from hepatoma cells. 2002;35:1237-1246 1274-1276 (Editorial) liver diseases to metabolic disorders, Li S (see Ujhazy P et al). 2002;35:246 —, McMahon BJ, Bodenheimer H. and back to clinical hepatology. 2002; (Correction) Chronic hepatitis B guidelines: East 35:497-499 (Editorial) Li T (see Kerkweg U et al). 2002;35:560- versus West. 2002;35:98 1-982 Margenthaler JA (see Shimizu Y et al). 567 (Correspondence) 2002;35:805-814 Liang TJ (see Lau JYN et al). 2002;35: Long SA (see Sasaki M et al). 2002;35: Marques D (see Pandak WM et al). 2002; 1002-1009 (Perspectives in Clinical 1284-1286 (Correspondence) 35:1400-1408 Hepatology) Longo C (see Arvelo MB et al). 2002;35: Martell M (see Buti M et al). 2002;35:930- Liaw Y-F (see Hsu Y-S et al). 2002;35: 535-543 936 1522-1527 Lopes AR (see Ma Y et al). 2002;35:658- Martin JL (see Bourdi M et al). 2002;35: —. Chronic hepatitis B guidelines: East 664 289-298 versus West. 2002;35:979-981 Lépez M-P (see Solaun MS et al). 2002;35: Martin-Sanz P (see Callejas NA et al). (Correspondence) 1104-1116 2002;35:341-348 Liddle C (see Chitturi S et al). 2002;35: Léw-Baselli A (see Grasl-Kraupp B et al). Martinez-Chantar ML (see Ansorena E et 373-379 2002;35:1372-1380 al). 2002;35:274-280 Lin R (see Chitturi S et al). 2002;35:373- Lowell BB (see Baffy G et al). 2002;35:753- Marzioni M (see Alpini G et al). 2002;35: 379 761 1041-1052 Lindor KD (see Angulo P et al). 2002;35: Lu SC (see Ansorena E et al). 2002;35:274- Masini E (see Fantappié O et al). 2002;35: 1494-1500 280 843-852 — (see Charlton M et al). 2002;35:898-904 Lubin I (see Galun E et al). 2002;35:673- Masubuchi Y (see Bourdi M et al). 2002; — (see Joshi S et al). 2002;35:409-413 679 35:289-298 1570 AUTHOR INDEX HEPATOLOGY, June 2002 —, Nakayama S, Horie T. Role of McIntyre N. Obituary. Professor Dame Miner C (see Rosen HR et al). 2002;35: mitochondrial permeability transition Sheila Sherlock. 2002;35:507-509 190-198 in diclofenac-induced hepatocyte McKellar L (see Ortiz D et al). 2002;35: Ming Z, Smyth DD, Lautt WW. Decreases injury in rats. 2002;35:544-551 1548 (Correspondence) in portal flow trigger a hepatorenal Masuda T (see Oka Y et al). 2002;35:1153- McMahon B] (see Lok ASF et al). 2002;35: reflex to inhibit renal sodium and 1163 981-982 (Correspondence) water excretion in rats: role of Mato JM (see Ansorena E et al). 2002;35: Mecca F (see Pagano G et al). 2002;35:367- adenosine. 2002;35:167-175 274-280 372 Miquel JF (see Rigotti A et al). 2002;35: Matot E (see Galun E et al). 2002;35:673- Medina I (see Obrador E et al). 2002;35: 240-241 (Correspondence) 679 74-81 Miracolo A (see Mazzella G et al). 2002;35: — (see Galun E et al). 2002;35:986 Medina JF (see Melero S et al). 2002;35: 1291 (Correction) (Correction) 1513-1521 Misra S (see Ujhazy P et al). 2002;35:246 Matsumoto A (see Umemura T et al). Mehta S (see Streiff MB et al). 2002;35: (Correction) 2002;35:953-959 947-952 Missale G (see Penna A et al). 2002;35: Matsumura M (see Ijichi M et al). 2002;35: — (see Sulkowski MS et al). 2002;35:182- 1225-1236 853-860 189 Mitchell C (see Mallet VO et al). 2002;35: Matsumura S, Van De Water J, Kita H, Meier PJ (see Kullak-Ublick GA et al). 799-804 Coppel RL, Tsuji T, Yamamoto K, 2002;35:732-733 (Correspondence) Mitchell S (see Boberg KM et al). 2002;35: Ansari AA, Gershwin ME. Meijer K (see Lisman T et al). 2002;35: 652-657 Contribution to antimitochondrial 616-621 Miura T (see Shiota G et al). 2002;35: antibody production: cleavage of Meisel H (see Preikschat P et al). 2002;35: 1125-1133 pyruvate dehyrogenase complex-E2 by 466-477 Miyaijma A (see Kamiya A et al). 2002;35: apoptosis-related proteases. 2002;35: Melero S, Spirli C, Zsembery A, Medina 1351-1359 14-22 JF, Joplin RE, Duner E, Zuin M, Miyakawa H (see Shibuya A et al). 2002; Matsushima-Nishiwaki R (see Adachi S et Neuberger JM, Prieto J, Strazzabosco 35:1172-1178 al). 2002;35:332-340 M. Defective regulation of Miyakawa Y (see Kato H et al). 2002;35: Matsushita M (see Tahashi Y et al). 2002; cholangiocyte Cl-'/HCO; and Na*/ 922-929 35:49-61 H* exchanger activities in primary Miyamura T (see Tsutsumi T et al). 2002; Matsuura Y (see Tsutsumi T et al). 2002; biliary cirrhosis. 2002;35:1513-1521 35:937-946 35:937-946 Melinek J] (see Amersi F et al). 2002;35: Mizokami M (see Kato H et al). 2002;35: Matsuzaki K (see Tahashi Y et al). 2002;35: 815-823 922-929 49-61 Mendoza L (see Solaun MS et al). 2002;35: Mizrachi S (see Galun E et al). 2002;35: Matszawa Y (see Imai Y et al). 2002;35: 1104-1116 673-679 974-976 (€ ‘orrespondence) Meng L-J, Wang P, WolkofAfW , Kim — (see Galun E et al). 2002;35:986 Mazzanti R (see Fantappié O et al). 2002; RB, Tirona RG, Hofmann AF, Pang (Correction) 35:843-852 KS. Transport of the sulfated, Mazzella G, Rizzo N, Azzaroli F, Simoni P, amidated bile acid, Moitinho E (see Escorsell A et al). 2002;35: Bovicelli L, Miracolo A, Simonazzi G, sulfolithocholyltaurine, into rat 385-392 — (see Garcia-Retortillo M et al). 2002;35: Colecchia A, Nigro G, Mwangemi C, hepatocytes is mediated by Oatp1] and 680-687 Festi D, Roda E. Ursodeoxycholic Oatp2. 2002;35:1031-1040 — (see Perello A et al). 2002;35:132-139 acid administration in patients with Menon KVN (see Czaja AJ et al). 2002;35: Mol O (see Plass JRM et al). 2002;35:589- cholestasis of pregnancy: effects on 890-897 primary bile acids in babies and Merenda R (see Bolognesi M et al). 2002; 596 Molinero L-M (see Bafiares R et al). 2002; mothers. 2002;35:1291 (Correction) 35:60 1-608 Mazzocchi V (see La Villa G et al). 2002; Merkel C (see Bolognesi M et al). 2002;35: 35:609-615 Monti J (see de Lujan Alvarez M et al). 35:1441-1448 601-608 McCuskey RS (see Slehria S et al). 2002;35: — (see Riggio O et al). 2002;35:501-502 2002;35:824-833 1320-1328 (Correspondence) Moore RD (see Sulkowski MS et al). 2002; McFarlane IG (see Heneghan MA et al). Merli M (see Riggio O et al). 2002;35:501- 35:182-189 2002;35:7-13 (Perspective in Clinical 502 (Correspondence) Moradpour D (see Brass V et al). 2002;35: Hepatology) Mezey E (see Mallet VO et al). 2002;35: 722-723 (Hepatology Elsewhere) McGill JM (see Alpini G et al). 2002;35: 799-804 — (see Gosert R et al). 2002;35:724-726 1256-1268 (Special Article) Mieli-Vergani G (see Ma Y et al). 2002;35: (Hepatology Eewhere) McGovern B, Bica |. Risk of HAART 658-664 Mori C (see Penna A et al). 2002;35:1225- therapy in hepatitis C. 2002;35:730 Migita K (see Abiru S et al). 2002;35:1117- 1236 (€ ‘orrespondence) 1124 Moritmoto M, Sugimori K, Shirato K, McHutchison JG (see Di Bisceglie AM et Mihara K (see Ninomiya T et al). 2002;35: Kokawa A, Tomita N, Saito T, Tanaka al). 2002;35:224-231 (Special Article) 82-87 N, Nozawa A, Hara M, Sekihara H, —, Poynard T, Esteban-Mur R, Davis Mihm S (see Frese M et al). 2002;35:694-703 Shimada H, Imada T, Tanaka K. GL, Goodman ZD, Harvey J, Ling Mifiana JB, Gomez-Cambronero L, Lloret Treatment of hepatocellular carcinoma M-H, Garaud JJ, Albrecht JK, Patel A, Pallardé FV, Del Olmo J, Escudero with radiofrequency ablation: K, Dienstag JL, International A, Rodrigo JM, Pellin A, Vifia JR, Radiologic-histologic correlation during Hepatitis Interventional Therapy Vifia J, Sastre J. Mitochondrial follow-up periods. 2002;35:1467-1475 Group. Hepatic HCV RNA before oxidative stress and CD95 ligand: a Moriwaki H (see Adachi S et al). 2002;35: and after treatment with interferon dual mechanism for hepatocyte 332-340 alone or combined with ribavirin. apoptosis in chronic alcoholism. Moriya K (see Tsutsumi T et al). 2002;35: 2002;35:688-693 2002;35:1205-1214 937-946